World's Best Scientists 2026 revealed!
Timothy Kottke

Timothy Kottke

D-Index & Metrics

Biology and Biochemistry

D-Index
62
Citations
10183
World Ranking
11054
National Ranking
4777

Overview

Timothy Kottke is affiliated with the Mayo Clinic in the United States and has contributed to research primarily in the fields of Medicine, Biochemistry, Genetics and Molecular Biology, and Immunology and Microbiology. Their work encompasses several subfields including Genetics, Immunology, Oncology, Molecular Biology, and Infectious Diseases.

The scientist's research topics are centered around immunotherapy and immune responses, CAR-T cell therapy research, virus-based gene therapy, ocular oncology and treatments, vaccines and immunoinformatics approaches, glioma diagnosis and treatment, and viral infectious diseases with gene expression in insects.

Timothy Kottke has published in a variety of scientific journals. Frequent publication venues include:

  • Nature Communications
  • Frontiers in Immunology
  • Neuro-Oncology
  • Molecular Therapy - Oncolytics
  • International Journal of Environmental Research and Public Health

Their most recent papers include:

  • Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy, 2021, Nature Communications
  • APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy, 2020, Nature Communications
  • A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses, 2023, Frontiers in Immunology
  • Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors, 2020, Neuro-Oncology
  • Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses, 2023, Molecular Therapy - Oncolytics

Frequent collaborators in their research include Richard G. Vile, Jason M. Tonne, Jill Thompson, José S. Pulido, and Christopher B. Driscoll. These collaborators have coauthored multiple papers with Kottke, contributing to the development of research projects and publications.

Best Publications

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

    Adel Samson;Karen J. Scott;David Taggart;Emma J. West

  • Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.

    Rosa Maria Diaz;Feorillo Galivo;Timothy Kottke;Phonphimon Wongthida

  • Caspase‐6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation

    Sandrine Ruchaud;Nadia Korfali;Pascal Villa;Timothy J. Kottke

  • Comparison of Apoptosis in Wild-Type and Fas-Resistant Cells: Chemotherapy-Induced Apoptosis Is Not Dependent on Fas/Fas Ligand Interactions

    Christine M. Eischen;Timothy J. Kottke;Timothy J. Kottke;Luis M. Martins;Luis M. Martins;Guriqbal S. Basi;Guriqbal S. Basi

  • G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells

    April L. Blajeski;Vy A. Phan;Timothy J. Kottke;Scott H. Kaufmann

  • Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

    Robin J. Prestwich;Elizabeth J. Ilett;Fiona Errington;Rosa M. Diaz

  • Activation of Multiple Interleukin-1β Converting Enzyme Homologues in Cytosol and Nuclei of HL-60 Cells during Etoposide-induced Apoptosis

    Luis M. Martins;Timothy Kottke;Peter W. Mesner;Guriqbal S. Basi

  • Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

    Robin J. Prestwich;Fiona Errington;Elizabeth J. Ilett;Ruth S.M. Morgan

  • Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy

    Candice Willmon;Kevin Harrington;Timothy Kottke;Robin Prestwich

  • Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus

    Jian Qiao;Hongxun Wang;Timothy Kottke;Christine White

  • Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

    Caroline Cole;Jian Qiao;Timothy Kottke;Rosa Maria Diaz

  • Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.

    Evanthia Galanis;Svetomir N Markovic;Vera J Suman;Gerard J Nuovo

  • Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy

    Jian Qiao;Timothy Kottke;Candice Willmon;Feorillo Galivo

  • Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

    Karishma Rajani;Christopher Parrish;Timothy Kottke;Jill Thompson

  • Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis.

    Luis M. Martins;Peter W. Mesner;Peter W. Mesner;Timothy J. Kottke;Timothy J. Kottke;Guriqbal S. Basi;Guriqbal S. Basi

  • Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

    E J Ilett;R J Prestwich;T Kottke;F Errington

  • Flavopiridol Binds to Duplex DNA

    Keith C. Bible;Roy H. Bible;Timothy J. Kottke;Phyllis A. Svingen

  • Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

    Benjamin M. F. Mow;Benjamin M. F. Mow;Benjamin M. F. Mow;Joya Chandra;Joya Chandra;Joya Chandra;Phyllis A. Svingen;Phyllis A. Svingen;Phyllis A. Svingen;Christopher G. Hallgren;Christopher G. Hallgren;Christopher G. Hallgren

  • Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution.

    Kumiko Samejima;Shigenobu Toné;Timothy J. Kottke;Masato Enari

Frequent Co-Authors

Richard G. Vile
Richard G. Vile Mayo Clinic
Alan Melcher
Alan Melcher Institute of Cancer Research
Peter Selby
Peter Selby University of Leeds
Kevin J. Harrington
Kevin J. Harrington Royal Marsden NHS Foundation Trust
Matthew C. Coffey
Matthew C. Coffey Oncolytics Biotech (Canada)
William C. Earnshaw
William C. Earnshaw University of Edinburgh
Glen N. Barber
Glen N. Barber University of Miami
Atique U. Ahmed
Atique U. Ahmed Northwestern University
Reuben S. Harris
Reuben S. Harris The University of Texas Health Science Center at San Antonio

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Timothy Kottke

Trending Scientists

Recently Published Articles